Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study by 동재준
molecules
Article
Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor?
A Comparative Study
Mohammad Hassan Baig 1 , Tanuj Sharma 1 , Irfan Ahmad 2 , Mohammed Abohashrh 3,
Mohammad Mahtab Alam 3 and Jae-June Dong 1,*


Citation: Baig, M.H.; Sharma, T.;
Ahmad, I.; Abohashrh, M.; Alam,
M.M.; Dong, J.-J. Is PF-00835231 a
Pan-SARS-CoV-2 Mpro Inhibitor?
A Comparative Study. Molecules 2021,
26, 1678. https://doi.org/10.3390/
molecules26061678
Academic Editors: Marco Tutone and
Anna Maria Almerico
Received: 3 February 2021
Accepted: 4 March 2021
Published: 17 March 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Family Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Korea; mohdhassanbaig@gmail.com (M.H.B.); tanush84@gmail.com (T.S.)
2 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University,
Abha 61421, Saudi Arabia; irfancsmmu@gmail.com
3 Department of Basic Medical Sciences, College of Applied Medical Sciences, King Khalid University,
Abha 61421, Saudi Arabia; mabuhashra@kku.edu.sa (M.A.); mmalam@kku.edu.sa (M.M.A.)
* Correspondence: s82tonight@yuhs.ac
Abstract: The COVID-19 outbreak continues to spread worldwide at a rapid rate. Currently, the ab-
sence of any effective antiviral treatment is the major concern for the global population. The reports
of the occurrence of various point mutations within the important therapeutic target protein of SARS-
CoV-2 has elevated the problem. The SARS-CoV-2 main protease (Mpro) is a major therapeutic target
for new antiviral designs. In this study, the efficacy of PF-00835231 was investigated (a Mpro inhibitor
under clinical trials) against the Mpro and their reported mutants. Various in silico approaches were
used to investigate and compare the efficacy of PF-00835231 and five drugs previously documented
to inhibit the Mpro. Our study shows that PF-00835231 is not only effective against the wild type but
demonstrates a high affinity against the studied mutants as well.
Keywords: SARS-CoV-2; main protease; mutants; inhibitors; PF-00835231
1. Introduction
SARS-CoV-2, the etiological agent of COVID-19, is a pandemic responsible for claiming
over a million human lives [1]. More than a thousand drugs are currently in the COVID-
19 treatment pipeline; most of which are in the discovery stage and many of these are
existing treatments for other conditions currently being evaluated for SARS-CoV-2 [2].
The latest statistics available from ClinicalTrials.gov, a directory of clinical trials funded by
the US National Library of Medicine, reveal that 4371 studies are registered worldwide
and are growing day by day. Twenty-five trials, including using the most common drug,
Hydroxychloroquine, were discontinued [3]. To date only two studies are found in the
category of ‘Approved for marketing’, which are expanded access to convalescent plasma
and the drug molecule Remdesivir [4,5]. As an urgent consequence of the novelty of
SARS-CoV-2 infections and the lack of appropriate drugs, a wide range of techniques
and methods are being used to tackle the emerging worldwide COVID-19 pandemic.
To date, the therapies suggested are mainly the repurposing of existing drugs chosen for
the similarity of their initial indication such as antivirals/antiretrovirals or for the similarity
of their mode of action [6,7].
Pp1a and pp1ab polyproteins are formed by SARS-CoV-2 and are processed by two vi-
rally encoded cysteine proteases; the main protease (Mpro) and the papain-like protease [8].
In the viral replication process, it is apparent that the action of the Mpro is vital as it pro-
cesses the p1a/p1ab polyprotein virus proteolytically at more than 10 junctions to produce
a set of non-structural proteins (NSPs) essential for virus replication and transcription
including RdRp, helicase and the Mpro itself [9]. Of all recognized forms of coronaviruses,
the Mpro is the most explored target for drug development because it has almost the same
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mechanism and active site as MERS-CoV (Middle East Respiratory Syndrome Coronavirus)
and SARS-CoV [10,11].
Despite the lower mutation rate of the virus, studies have revealed more than 12,000
SARS-CoV-2 genome mutations. Many mutations would not impact the capacity of the
virus to transmit or trigger illness because they do not alter the structure of a protein
and certain mutations that change proteins are often more likely to damage the virus
than to strengthen it [12]. A few vaccines have recently been approved and more than
50 are in different phases of trials. Structural protein mutations that are attacked by the
host immune system can impede vaccine efficacy and non-structural protein mutations
can develop strains that are resistant to antivirals. Different strains of the virus that are
more transmittable than the wild type SARS-CoV-2 have recently been identified in South
Africa. In the United Kingdom and several other nations including Europe and Brazil,
the extensive spreading of coronavirus variants has placed the world on alert and sparked
a new lockdown [13,14]. It picks up minor changes to the genetic code every time the SARS-
CoV-2 moves from person to person but researchers are beginning to find variations of how
the virus mutates. A major research investment is being made towards the development of
new therapeutics or repurposing old drugs as weapons against COVID-19.
Pfizer has started clinical trials (phase I) with a small molecule PF-07304814 that
targets the Mpro of SARS-CoV-2 [15]. It may prove to be the first antiviral drug to target
this protein (Mpro) to combat COVID-19. PF-07304814 comprises a phosphate group that
renders the compound soluble and cleaves the active antiviral PF-00835231 by alkaline
phosphatase enzymes in the tissue [15].
Here in this study, we evaluate the binding efficacy of six known inhibitors of the
Mpro (Figure 1). The binding efficacy of these inhibitors was measured against the WT and
the mutant Mpro (Figure 2). Five drugs (bedaquiline, boceprevir, efonidipine, manidipine
and lercanidipine) have been earlier reported to inhibit Mpro activity to below 40 µM [11].
The sixth inhibitor, PF-00835231, is a powerful inhibitor of the SARS-CoV-2 Mpro with
sufficient medicinal properties to merit further research as an intravenous COVID-19
therapy [16]. During the 2002–2003 SARS epidemic, PF-00835231 was first discovered by
Pfizer chemists to target the SARS-CoV Mpro [16]. Infections petered out, however, and the
compound was put on hold along with a collection of other possible coronavirus antivirals.
In addition to demonstrating action against two strains of SARS-CoV-2, PF-00835231 was
able to kill other coronaviruses in cells as well [15]. PF-00835231 is the active form of
PF-07304814 currently being tested (phase 1) in patients with a SARS-CoV-2 infection and
mild to moderate symptoms [3,15].
This study involves a state of the art computational evaluation to assess the compara-
tive efficacy of PF-00835231 and other reported inhibitors against the wild type and four
reported Mpro mutants. We hypothesize here that PF-00835231 might be less competitive
against various SARS-CoV-2 virus mutants; even the results of experimental and clinical
studies are still to offer clearer results.
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Figure 1. Structure of all of the compounds investigated in this study. (a) PF-00835231; (b) Boceprevir; (c) Manidipine;
(d) Efonidipine; (e) Lercanidipine; (f) Bedaquiline.
Figure 2. The selected mutant investigated in this study.
2. Result and Discussion
In this study, a comparative analysis of the efficacy of PF-00835231 and five drugs pre-
viously documented to inhibit the Mpro (bedaquiline, boceprevir, efonidipine, manidipine
and lercanidipine) was performed with the wild type and four reported Mpro mutants
(Mutant 1 (Y54C), Mutant 2 (N142S), Mutant 3 (T190I) and Mutant 4 (A191V)).
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It was found that in all of the modeled structures, no residues lay in the disallowed
region, confirming the significant quality of the structures (Supplementary Figure S1).
An ERRAT analysis of all of the structures was also investigated [17]. It was found that the
overall structural quality of the modeled structure was very good. A VERIFY_3D [18,19]
analysis was also performed and it was found that in all of the modelled structures
more than 94% of the residues had an average 3D–1D score > 0.2, proving the great
compatibility between the primary sequence to the tertiary structure. Before conducting
the molecular docking experiments, the validation of the molecular docking protocol was
performed. Different crystal structures of the inhibitor bound SARS-CoV-2 Mpro were
retrieved. The binding orientation of the redocked poses was found to be similar to the
crystal confirmation of the inhibitor (Supplementary Figure S2 and Table S1). Most of the
redocked poses of the inhibitors were found to share a root mean square deviation (RMSD)
less than 1 Å (for small molecule inhibitors) than its crystal counterpart (Supplementary
Figure S2 and Table S1).
In order to determine the predictive binding effectiveness of small molecules with
receptors, a molecular docking evaluation is usually carried out [20]. Six compounds
(PF-00835231, bedaquiline, boceprevir, efonidipine, manidipine and lercanidipine) were
minimized and prepared for screening within the active site of the Mpro (WT) and modeled
Mpro mutants. In terms of the PLP fitness score using GOLD tools, the binding efficacy
score of all six selected compounds was calculated.
PF-00835231 was found to be the most effective against the WT Mpro (PLP Fitness
score 83.13 (Table 1). This compound was found to be very effective against other selected
mutants as well (Tables 2–5). Compared with other selected compounds, PF-00835231
was found to be the most effective inhibitor against Y54C and A191V (Tables 2 and 5)
(Figure 3) whereas efonidipine was found to be most effective against N142S and T190I
(Tables 3 and 4) (Figure 4). Figures 3 and 4 show the binding of PF-00835231 and efonidip-
ine against the Mpro and the selected mutants. The study also highlighted the important
residues playing a crucial role in accommodating the selected compounds within the active
site of the Mpro and the mutants. It was also found that the large number of active site
residues of the Mpro (WT and mutant) were actively participating in the positioning of all
of the molecules. Tables 1–5 represent the details of the interacting residues (amino acid)
of the Mpro and mutants interacting with all of the selected molecules. L141, S144, H164,
E166, Q189 and Q192 were found to be very prominently involved in making hydrogen
bonds with all of the selected compounds (Tables 1–5) (Figures 3 and 4). The crucial role
of these residues has been discussed earlier as well [21–23]. Other residues found to be
playing an important role in the binding were T25, T26, L27, H41, M49, C145, M165, L167,
P168, D187 and R188 (Tables 1–5) (Figures 3 and 4 and Supplementary Figures S3–S7).
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Figure 3. Complex of PF-00835231 within the active site of (a) WT; (b) Y54C.
Figure 4. Complex of Efonidipine within the active site of (a) N142S; (b) T190I.
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Table 1. The binding details of all compounds against the WT Mpro.
Protein Inhibitor Score
Residues
Hydrogen Bond Pi Interactions
WT
PF-00835231 83.13 G143, C145, H164, E166, Q189 H41, P168
Manidipine 72.93 F140, N142, E166 H41, L141, M165
Boceprevir 67.42 N142, E166, Q189 H41, M49, C145
Lercanidipine 69.73 Q189, Q192 C145, M165, L167, P168
Efonidipine 71.23 H41, C145, M165, P168, A191
Bedaquiline 66.92 N142 H41
Table 2. The binding details of all compounds against the Mutant 1 (Y54C) Mpro.
Protein Inhibitor Score
Residues
Hydrogen Bond Pi Interactions
Mutant 1 (Y54C)
PF-00835231 73.17 L141, G143, S144, C145, E166, Q189 M49, P168
Manidipine 66.68 T26, S46 C145, M165
Boceprevir 65.96 T26, G143, C145, E166, Q189 H41, M49, H163, M165
Lercanidipine 65.28 T26, G143, C145 L27, H41, M165
Efonidipine 68.23 L141, G143, S144, Q189 L27, C145, H163, P168, H172
Bedaquiline 63.27 H164 L27, H41, M49, C145
Table 3. The binding details of all compounds against the Mutant 2 (N142S) Mpro.
Protein Inhibitor Score
Residues
Hydrogen Bond Pi Interaction
Mutant 2 N142S
PF-00835231 76.53 L141, S142, G143, E166, Q189 S144, C145, L167, P168
Manidipine 68.64 F140, E166 L141, M165
Boceprevir 65.33 Q189 C44, M49, C145, H163, M165
Lercanidipine 69.05 L27, M49, C145, H163
Efonidipine 87.05 S142, C145 L27, M49, M165, L167
Bedaquiline 68.83 H164 H41, M49, C145, M165
Table 4. The binding details of all compounds against the Mutant 3 (T190I) Mpro.
Protein Inhibitor Score
Residues
Hydrogen Bond Pi Interactions
Mutant 3 T190I
PF-00835231 70.66 E166, D187, Q189 C44, M49, C145, H163, M165
Manidipine 63.42 F140, N142 M49, L141, M165
Boceprevir 60.36 N142 C44, T45, M165
Lercanidipine 66.96 T26 L27, H41, C44, M49, C145, M165
Efonidipine 72.25 F140, E166 L141, H163, M165, H172
Bedaquiline 67.87 E166 H41, C145
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Table 5. The binding details of all compounds against the Mutant 4 (A191V) Mpro.
Protein Inhibitor Score
Residues
Hydrogen Bond Pi Interaction
Mutant 4 A191V
PF-00835231 73.61 L141, G143, S144, C145, Q189 M165, P168, H172, V191
Manidipine 65.95 T25, S46, N142 M165
Boceprevir 62.08 S46, Q189 C44, M49, M165
Lercanidipine 67.93 C44, S46, N142 H41, M49, C145, M165
Efonidipine 71.01 F140 L141, H163, M165, P168
Bedaquiline 59.99 N142 H41, C145, M165
Recent studies have shown that all of the compounds (bedaquiline, boceprevir, efoni-
dipine, manidipine and lercanidipine) specified in this study carry the potential to inhibit
the Mpro with IC50 values below 40 µM [11]. The binding affinity for PF-00835231 has
been reported to be in the nano molar range [15]. Our in depth in silico analysis also found
PF-00835231 to be carrying a high affinity against the Mpro (WT) compared with other
selected compounds. We also hypothesized that these compounds, including PF-00835231,
might prove to be effective against the mutants as well. Boceprevir, which is a protease
inhibitor and was originally used to treat hepatitis, has been well studied to carry an
inhibitory potential against the Mpro [24–26]. This compound was found to carry a very
low affinity against the T190I whilst being the most active against the WT. The high binding
affinity of this compound against the Mpro (WT) has been reported in several studies [25].
This compound was found to be moderately effective against the WT and the selected
mutants. Likewise, other compounds considered in this study showed a moderate affinity
against all of the selected mutants. Manidipine [27], which is a calcium channel blocker
and is an approved antihypertensive drug, was found to be very effective against the WT.
Several studies have reported the potential of manidipine against SARS-CoV-2 [11,28,29].
This compound showed moderate activity against other selected mutants. Lercanidip-
ine [30], another calcium channel blocker and an approved antihypertensive drug, was
also found to show moderate activity against all of the selected targets and was most active
against the WT and N142S. Bedaquiline [31], another compound considered in this study,
is an approved drug for the treatment of active tuberculosis. This compound was found to
be moderately active against all of the selected proteins with a maximum binding affinity
against N142S and a least binding affinity against A191V.
Considering the high efficacy of PF-00835231 and Efonidipine against all of the selected
proteins, we further studied the structure dynamics of WT and the Mpro mutants in
complex with these two inhibitors (Figure 5). Root mean square deviation (RMSD) is a very
significant parameter to explore the protein dynamics in terms of conformational changes
within the protein structure. The backbone RMSD plot revealed that in the presence of
PF-00835231, the structures of the WT, Y54C and T190I mutants were stable throughout
the 100 ns simulation while the structures of N142S and A191V indicated fluctuations after
50 ns (Figure 5a). The backbone of WT and N142S was found to be stable in the Efonidipine
bound structure (Figure 5b) while other mutants, namely Y54C, A191V and T190I, showed
fluctuations in the backbone. Our overall investigation found that Efonidipine caused
fewer structural variations in the backbone of WT and N142S while PF-00835231 caused
fewer structural variations in the WT, Y54C and T190I mutants. This suggested that
the association of PF-00835231 within the active site of the Mpro and its mutant was
comparatively more stable. Further, the ligand RMSD plot was also analyzed and it
was observed that PF-07304814 was more stable with WT, Y54C and N142S throughout
the simulation time period compared with Efonidipine (Figure 5c,d). These analyses
further provide a strong support that the PF-07304814 bound complexes were very stable.
The Hbond analysis also showed that the PF-00835231 bound complexes comparatively
made more hydrogen bonds than the Efonidipine bound complexes (Figure 5e,f). This
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finding well supports the theory that the stability of PF-07304814 within the active site of
the Mpro (WT) and its mutants may be because of the greater number of Hbonds providing
the stability to PF-07304814. The overall outcome of this study showed that PF-07304814
could be a very potent inhibitor against the Mpro and its other reported mutants.
Figure 5. Molecular dynamics results of the PF-07304814 and Efonidipine bound complexes of the WT Mpro (black),
Y54C (yellow), N142S (green), T190I (blue) and A1901V (red). The backbone RMSD of the Mpro (WT) and mutants in
complex with (a) PF-07304814; (b) Efonidipine. The ligand RMSD of (c) PF-07304814 and (d) Efonidipine during the 100 ns.
The intermolecular hydrogen bond formations of the (e) PF-07304814 and (f) Efonidipine bound complex.
3. Materials and Methods
3.1. Protein Structure Preparation
Here in this study, the crystal structure of the SARS-CoV-2 (COVID-19) Mpro in
complex with inhibitor UAW248 was retrieved from the RCSB protein databank (pdb id:
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6xbi) [32,33]. The crystal bound inhibitor and other heteroatoms were removed. The struc-
ture of the mutants was prepared using the molecular modeling technique. The amino acid
sequence of all of the selected mutants (Y54C, N142S, T190I and A191V) were retrieved
from the NCBI protein database (GenBank: QJD23268.1, QJC19621.1, QJA16866.1 and
QIZ14843.1) [34]. To model the structure of the mutants, the 6xbi was taken as a template.
The structures were modelled using the modeler 9.23 [35]. All of the modeled structures
were validated using various in silico tools [36,37]. The structure of all of the Mpro mutants
was modeled and validated as well. The Ramachandran plot was computed for all of the
modeled structures using the PROCHECK module of SAVES [38]. All of the structures
were subjected to energy minimization using the steepest descent method for 1000 steps.
3.2. Ligand Structure Preparation
The 3D structure of bedaquiline (CID: 5388906), boceprevir (CID: 10324367), efoni-
dipine (CID: 119171), lercanidipine (CID: 65866), manidipine (CID: 4008) and PF-00835231
(CID: 11561899) were retrieved from the PubChem structure database [39]. All of the
compounds were energy minimized using the conjugate gradient method for 1000 steps in
UCSF Chimera [40].
3.3. Redocking: Co-Crystallized Ligand Pose Validation Study
Several crystal structures of the inhibitor bound SARS-CoV-2 Mpro were retrieved
from the RCSB protein databank. The inhibitors were separated and were subjected to
a redock within the structure of the Mpro using CCDC GOLD [41]. The docked confir-
mation of the inhibitors within the active site of the Mpro was compared with the crystal
orientations.
3.4. Virtual Screening
All of the selected compounds were subjected to docking within the active site of WT
and selected Mpro mutants using Gold 2.2 (CCDC, Cambridge, UK) [41]. The selection was
made based on their PLP fitness score. The complexes were visualized using PyMol [42]
and a discovery studio visualizer.
3.5. Molecular Dynamics Simulation
The selected complexes were subjected to a molecular dynamics simulation to investi-
gate the stability of these molecules (in complex with WT and mutant Mpro). The molec-
ular dynamics simulation was performed with GROMACS [43,44]. The complexes of
PF-00835231 and efonidipine complexed with the Mpro (WT) and mutants prepared us-
ing the molecular docking were considered as a starting point for MD study. Here we
used a GROMACS 2020.4 package with a Charmm36 force field to perform the MD sim-
ulation [45]. GROMACS is a widely used tool for performing MD simulation studies
and its utilization in protein-ligand simulation has been reported in a large number of
studies [46,47]. The parameter files for all the ligands were generated using SwissParam
(https://www.swissparam.ch/, accessed on 15 January 2021), which is an online tool
for generating parameters for the Charmm force field. The complexes were solvated
within the dodecahedron box of an explicit TIP3P water model with a 0.1 nm margin
between the box walls and solute. Na+ or Cl− counterions were added to neutralize the
system charge [48,49]. The particle mesh Ewald method (cutoff distance of 0.1 nm) was
employed for calculating the long-range electrostatic interactions [50]. The Lennard-Jones
6–12 potential was used for evaluating the van der Waals interactions; for this calculation,
the cutoff distance was set to 0.1 nm. The LINCS algorithm was used to constrain the
bond lengths while setting the time step to 0.002 pico second [51,52]. Further energy
minimization was performed using the steepest descent method for 10,000 steps in order
to remove the steric clashes between atoms. The whole system was further subjected for
equilibration for 1 nano second (ns). To maintain the system at 300 K and 1 atm, Berendsen
weak coupling systems were utilized [53,54]. A Maxwell Boltzmann distribution was used
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for randomly generating the initial velocities. The final 100 ns production run was per-
formed at 300 K in an NPT ensemble. Furthermore, xmgrace was used to generated graphs
(http://plasmagate.weizmann.ac.il, accessed on 15 January 2021); PyMol and VMD were
used for further graphical inspections and analysis.
4. Conclusions
In conclusion, this study predicted that PF-00835231, which is already being tested
to target the SARS-CoV-2 Mpro, may also be potent against the specified Mpro mutants.
Notably, PF-00835231 and five other reported antivirals were investigated for comparative
inhibitory efficacy in terms of binding potency against WT and the Mpro mutants. PF-
00835231 was found to be the most efficient inhibitor of the Y54C and A191V Mpro mutants
with a fitness score of 73.17 and 73.61, respectively, relative to the other listed drugs. Based
on our research, it is early to determine but hopefully this potential drug PF-00835231
would most certainly be highly effective against the mutant Mpro and could prove to be a
sharp weapon in the fight against the COVID-19 pandemic.
Supplementary Materials: The following are available online: Figure S1: Validation of the modeled
structures of mutants (a) Y54C (b) N142S (c) T190I (d) A191V, Figure S2: The superimposed structure
of crystal pose (blue) of inhibitor and redocked pose of (a) X47 (green) (pdb id: 6wco), (b) X77 (yellow)
(pdb id: 6w63), and (c) ADRAFINIL (red) (pdb id: 7ans) within the binding site of Mpro, Figure
S3: Complex of (a) PF-00835231 (b) Boceprevir (c) Manidipine (d) Efonidipine (e) Lercanidipine (f)
Bedaquiline within the active site of WT, Figure S4: Complex of all (a) PF-00835231 (b) Boceprevir (c)
Manidipine (d) Efonidipine (e) Lercanidipine (f) Bedaquiline within the active site of Y54C, Figure S5:
Complex of all (a) PF-00835231 (b) Boceprevir (c) Manidipine (d) Efonidipine (e) Lercanidipine (f)
Bedaquiline within the active site of N142S, Figure S6: Complex of all (a) PF-00835231 (b) Boceprevir
(c) Manidipine (d) Efonidipine (e) Lercanidipine (f) Bedaquiline within the active site of T190I, Table
S1: The inhibitor bound crystal structure of SARS-CoV-2 Mpro considered for the validation of
docking protocol.
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